Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
Conditions
Brief summary
Establish the subjective improvement of genitourinary symptoms in breast cancer women at intervals defined by the study
Detailed description
To define the role of genito-urinary syndrome on quality of life, in particular on sexual function and mood wellbeing, in women with breast cancer before, during and after the treatment, Establish an improvement in tissue trophism throught gynecological evaluation, use of validated scales (Vaginal Health Index) and determination of the maturation index on vaginal cytology, Measurement of serum estradiol at set intervals before, during and after treatment
Interventions
Sponsors
Istituto Europeo Di Oncologia S.r.l.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establish the subjective improvement of genitourinary symptoms in breast cancer women at intervals defined by the study | — |
Secondary
| Measure | Time frame |
|---|---|
| To define the role of genito-urinary syndrome on quality of life, in particular on sexual function and mood wellbeing, in women with breast cancer before, during and after the treatment, Establish an improvement in tissue trophism throught gynecological evaluation, use of validated scales (Vaginal Health Index) and determination of the maturation index on vaginal cytology, Measurement of serum estradiol at set intervals before, during and after treatment | — |
Countries
Italy
Outcome results
None listed